This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
by Zacks Equity Research
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
by Zacks Equity Research
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
RHHBYNo Net Change BMYPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kymera's Eczema Drug Gets Fast Track Designation in the United States
by Zacks Equity Research
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
SNYNegative Net Change GILDNegative Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
by Kanishka Das
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
AZNNegative Net Change RHHBYNo Net Change BMYPositive Net Change MRKPositive Net Change
pharmaceuticals
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
by Sundeep Ganoria
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.
JNJPositive Net Change AMGNNegative Net Change ARGXNegative Net Change
biotechs medical pharmaceuticals
AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock
by Kinjel Shah
AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.
AZNNegative Net Change JNJPositive Net Change LLYPositive Net Change ABBVNegative Net Change
pharmaceuticals
Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank
by Shaun Pruitt
Adding to the unusually strong performance of the Russell 2000 this year, these top performers may certainly serve as stocks to add to your watchlist
BETRNegative Net Change COGTPositive Net Change CELCPositive Net Change RGCPositive Net Change OPENNegative Net Change IWMNegative Net Change
artificial-intelligence biotechnology earnings finance inflation interest-rate investing medical oncology-screening pharmaceuticals real-estate
Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III
by Zacks Equity Research
RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.
RHHBYNo Net Change LLYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?
by Ahan Chakraborty
LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.
NVOPositive Net Change LLYPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally?
by Zacks Equity Research
Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.
NVOPositive Net Change LLYPositive Net Change WVENegative Net Change
biotechs medical pharmaceuticals
GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?
by Kinjel Shah
GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.
AZNNegative Net Change GSKNegative Net Change NVOPositive Net Change LLYPositive Net Change
pharmaceuticals
Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
by Sundeep Ganoria
ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Top Research Reports for Broadcom, Exxon Mobil & Johnson & Johnson
by Mark Vickery
Broadcom rides surging AI semiconductor demand and VMware integration strength, even as margins tighten and debt remains a drag.
JNJPositive Net Change XOMNegative Net Change TRMBNegative Net Change AVGONegative Net Change SYFNegative Net Change ITICPositive Net Change APTVNegative Net Change FRDPositive Net Change
industrial-products insurance oil-energy pharmaceuticals semiconductor
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
by Ahan Chakraborty
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
by Kinjel Shah
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
pharmaceuticals
JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
by Kinjel Shah
JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.
JNJPositive Net Change PFEPositive Net Change
pharmaceuticals
Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
by Aparajita Dutta
Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVNegative Net Change PJPPositive Net Change IHEPositive Net Change PPHPositive Net Change
etfs pharmaceuticals
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
by Kinjel Shah
Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.
SNYNegative Net Change BMYPositive Net Change NVOPositive Net Change TEVANegative Net Change
pharmaceuticals
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?
by Kinjel Shah
Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
MRKPositive Net Change MRNAPositive Net Change CDTXPositive Net Change SMMTNegative Net Change
pharmaceuticals
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
by Zacks Equity Research
Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pharma ETF (XPH) Hits a New 52-Week High
by Sanghamitra Saha
Pharma ETF XPH hits a fresh 52-week high as healthcare shines amid AI bubble fears and slowing growth. Biotech M&A adds fuel -- can momentum hold?
XPHNo Net Change
etfs pharmaceuticals
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
by Zacks Equity Research
Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
RDYNegative Net Change TEVANegative Net Change SDZNYNegative Net Change
pharmaceuticals
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
by Ekta Bagri
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
BIIBPositive Net Change BMYPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?
by Kinjel Shah
J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.
JNJPositive Net Change AMGNNegative Net Change TEVANegative Net Change
pharmaceuticals